Beam Therapeutics CEO John M. Evans Reports Sale of $1.19 Million in Common Shares
Bitget2026/10/17 00:10- Beam Therapeutics CEO and director John M. Evans sold 50,000 common shares on October 15-16, 2026.
- Sales totaled 25,000 shares at $23.566 on October 15, with another 25,000 shares sold at $23.9838 on October 16.
- Evans exercised stock options for 25,000 common shares on each date at $1.03 per share.
- Direct common stock holdings stood at 1,047,205 shares following the transactions; indirect holdings totaled 103,000 shares through a trust.
- Remaining directly held stock options totaled 155,804, with an exercise price of $1.03.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin ETFs end two weeks of outflows

Worst-Performing Altcoins This Week as BTC Battles to Hold $80K: Weekend Watch

Goldman Sachs dramatically lowers KOSPI target from 12,000 to 9,000 points, still insists there is 60% upside potential
Goldman Sachs strategists have lowered their 12-month target for South Korea's KOSPI Index from 12,000 points to 9,000 points, representing a 25% decrease. Earlier this year, Goldman had raised the target multiple times. The latest downgrade is due to mounting concerns in the market over artificial intelligence (AI) trading.
